ADCs newly into human trials include Lilly's PTK7 and two bispecifics.
ApexOnco Front Page
Recent articles
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
Adverse events will be closely watched when full data are reported.
The Avanzar study could read out shortly.
First-in-human studies include a new pan-KRAS inhibitor and CDK2/4 degrader.
Satri-cel is filed for gastric cancer approval in China.
The company reckons its immunotherapy could improve on Keytruda.
